

# Chapter 255

## Botulinum Toxin

Richard G. Glogau

### REFERENCES

1. Erbguth FJ, Naumann M: Historical aspects of botulinum toxin: Justinus Kerner (1786–1862) and the “sausage poison.” *Neurology* **53**:1850, 1999 [PMID: 10563638]
2. DasGupta BR: Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystalline type A toxin. In: *Therapy with Botulinum Toxin*, edited by J Jankovic, M Hallett. New York, Marcel Dekker, 1994, p. 15
3. Schantz EJ, Johnson EA: Botulinum toxin: the story of its development for the treatment of human disease. *Perspect Biol Med* **40**:317, 1997 [PMID: 9167258]
4. Scott AB: Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. *Ophthalmology* **87**:1044, 1980 [PMID: 7243198]
5. Carruthers JD: Ophthalmologic use of botulinum A exotoxin. *Can J Ophthalmol* **20**:135, 1985
6. Tromovitch TA, Stegman SJ, Glogau RG: Zyderm collagen: implantation techniques. *J Am Acad Dermatol* **10**:273, 1984 [PMID: 6715595]
7. Carruthers JD, Carruthers JA: Treatment of glabellar frown lines with *C. Botulinum-A* exotoxin. *J Dermatol Surg Oncol* **18**:17, 1992 [PMID: 1740562]
8. Carruthers J, Carruthers A: The evolution of botulinum neurotoxin type A for cosmetic applications. *J Cosmet Laser Ther* **9**:186, 2007
9. Glogau RG: Treatment of hyperhidrosis with botulinum toxin. *Dermatol Clin* **22**:177, 2004
10. Kim CC et al: Predicting migraine responsiveness to botulinum toxin type A injections. *Arch Dermatol* **146**:159, 2010
11. Ranoux D et al: Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. *Ann Neurol* **64**:274, 2008 [PMID: 18546285]
12. Aoki KR: Evidence for antinociceptive activity of botulinum toxin type A in pain management. *Headache* **43**(Suppl. 1):S9, 2003
13. Aoki KR: Pharmacology and immunology of botulinum toxin serotypes. *J Neurol* **248**(Suppl. 1):3, 2001
14. Meunier FA et al: Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: The extent and duration are dictated by the sites of SNAP-25 truncation. *Mol Cell Neurosci* **22**:454, 2003 [PMID: 12727443]
15. Ascher B et al: A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. *J Am Acad Derm* **51**:225, 2004
16. Carruthers, JA et al: A Multicentre randomized, phase III study of a single dose of incobotulinumtoxin A, free from complexing proteins, in the treatment of glabellar frown lines. *J Dermatol Surg*, 2012 (in press)
17. Glogau RG: Hyperhidrosis and botulinum toxin A: patient selection and techniques. *Clin Dermatol* **22**:45, 2004

